PTC Therapeutics (NASDAQ: PTCT) CTO exercises options, sells 8,130 shares under 10b5-1 plan

Rhea-AI Filing Summary

PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported an options exercise and pre-planned share sale. He exercised stock options to acquire 8,130 shares of common stock at an exercise price of $38.10 per share and sold 8,130 shares in open-market transactions at weighted average prices in the mid-$85 range, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he holds 60,137 shares of PTC Therapeutics common stock directly and 2,737 shares indirectly through his spouse.

Insights

Equity compensation & insider trading analyst

Routine 10b5-1 exercise-and-sell by a senior executive, with sizable remaining holdings.

Neil Gregory Almstead, chief technical operations officer of PTC Therapeutics, exercised stock options to acquire 8,130 shares of common stock at an exercise price of $38.10 per share and sold 8,130 shares in open-market transactions. The filing states these sales were executed under a written Rule 10b5-1 trading plan adopted on November 11, 2025, indicating they were pre-arranged rather than opportunistic.

After the transactions, Almstead holds 60,137 common shares directly and 2,737 shares indirectly through his spouse, suggesting the activity represents a partial monetization rather than an exit. The presence of remaining stock option positions with an exercise price of $38.10 per share and expiration on January 6, 2032 indicates ongoing equity-based incentives, though the filing does not quantify their overall value or proportion of his total compensation.

Insider Trade Summary 10b5-1

Net Seller: 8,130 shares ($693,151)

Net Sell 7 txns

Insider Almstead Neil Gregory

Role CHIEF TECHNICAL OPS OFFICER

Sold 8,130 shs ($693K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	412	$0.00	--
Exercise	Stock Option (Right to Buy)	7,718	$0.00	--
Exercise	Common Stock	412	$38.10	$16K
Sale	Common Stock	412	$85.23	$35K
Exercise	Common Stock	7,718	$38.10	$294K
Sale	Common Stock	7,718	$85.26	$658K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 27,405 shares (Direct, null); Common Stock — 60,549 shares (Direct, null); Common Stock — 2,737 shares (Indirect, By Spouse)

Footnotes (1)

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.07 to $85.30 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable.

Key Figures

Shares sold: 8,130 shares Sale price block 1: $85.26 per share Sale price block 2: $85.23 per share +5 more

8 metrics

Shares sold 8,130 shares Open-market sales of common stock on June 26, 2026

Sale price block 1 $85.26 per share Weighted average price for 7,718 sold shares

Sale price block 2 $85.23 per share Weighted average price for 412 sold shares

Option exercise price $38.10 per share Exercise price for 8,130 stock option shares

Direct holdings after 60,137 shares Common stock held directly after transactions

Indirect holdings after 2,737 shares Common stock held indirectly via spouse after transactions

Options remaining block 1 19,687 options Stock options with $38.10 strike, expiring January 6, 2032

Options remaining block 2 27,405 options Stock options with $38.10 strike, expiring January 6, 2032

Key Terms

Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), open-market sale, +1 more

5 terms

Rule 10b5-1 plan regulatory

"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"This price represents the weighted average price of sale transactions that were executed in multiple trades"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 05:20 PM Accepted by SEC EDGAR 06/30/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		M(1)		412	A	$38.1	60,549	D
Common Stock	06/26/2026		S(1)		412	D	$85.23(2)	60,137	D
Common Stock	06/26/2026		M(1)		7,718	A	$38.1	67,855	D
Common Stock	06/26/2026		S(1)		7,718	D	$85.26(3)	60,137	D
Common Stock								2,737	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.1	06/26/2026		M(1)			412	(4)	01/06/2032	Common Stock	412	$0	27,405	D
Stock Option (Right to Buy)	$38.1	06/26/2026		M(1)			7,718	(4)	01/06/2032	Common Stock	7,718	$0	19,687	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.07 to $85.30 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PTC Therapeutics (PTCT) report for Neil Gregory Almstead?

PTC Therapeutics reported that Neil Gregory Almstead exercised stock options for 8,130 common shares at an exercise price of $38.10 per share and sold 8,130 shares in open-market transactions at weighted average prices in the mid-$85 range, under a pre-arranged Rule 10b5-1 plan.

How many PTC Therapeutics (PTCT) shares does Neil Gregory Almstead hold after the Form 4 transactions?

After the reported transactions, Neil Gregory Almstead holds 60,137 PTC Therapeutics common shares directly and 2,737 shares indirectly through his spouse. These holdings remain significant relative to the number of shares sold, indicating continued equity exposure to the company following the exercise-and-sell activity.

Were Neil Gregory Almstead’s PTC Therapeutics (PTCT) share sales pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a written Rule 10b5-1 trading plan adopted on November 11, 2025. Such plans pre-schedule transactions, which generally makes the timing of these sales less indicative of Almstead’s short-term view on PTC Therapeutics’ stock.

What prices did Neil Gregory Almstead receive for his PTC Therapeutics (PTCT) share sales?

The filing reports weighted average sale prices of $85.26 and $85.23 per share for different trade blocks. Footnotes explain these were aggregated from multiple trades executed in ranges between $85.00 and $85.75, with detailed price breakdowns available upon request.

What is the strike price and expiration for Neil Gregory Almstead’s exercised PTC Therapeutics (PTCT) options?

The exercised stock options had a conversion or exercise price of $38.10 per share and an expiration date of January 6, 2032. The filing notes that the options involved in these transactions were currently exercisable, reflecting long-dated equity incentives tied to PTC Therapeutics’ stock performance.